Monitor the Q2 2026 earnings release on August 6 for updates on aficamten nHCM regulatory discussions, omecamtiv mecarbil and ulacamten pipeline progress, and cash burn rate. The stock has historically moved +3.97% alpha at T+20 on prior reports, but this filing is a date announcement only.
Price Chart
Executive Summary
Cytokinetics announced it will report Q2 2026 results on August 6, 2026. The filing is a routine earnings date announcement with no financial results or guidance provided. The stock has shown a positive average alpha of +3.97% at T+20 across prior reports, but this filing contains no material new information to drive a directional move.
Key Facts
- Cytokinetics will report Q2 2026 financial results on August 6, 2026 at 4:00 PM ET
- Conference call scheduled for 4:30 PM ET on the same day
- No financial results, guidance, or business updates provided in this filing
- MYQORZO (aficamten) approved in U.S., Europe, and China for oHCM; positive Phase 3 ACACIA-HCM results for nHCM announced previously
Financial Impact
No financial data reported in this filing
Risk Factors
- No financial data or guidance provided to assess current performance
- Biotech pipeline risk: regulatory outcomes for aficamten in nHCM and development of omecamtiv mecarbil/ulacamten remain binary events
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3332536 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.60 (+5.35%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.60 (−9.45%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.60 (−7.49%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.60 (−9.00%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.60 (−18.43%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.60 (−18.63%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.60 (−18.75%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.60 (−19.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access